139 related articles for article (PubMed ID: 20732302)
1. Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase.
Pandey AV; Flück CE; Mullis PE
Biochem Biophys Res Commun; 2010 Sep; 400(3):374-8. PubMed ID: 20732302
[TBL] [Abstract][Full Text] [Related]
2. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
3. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.
Flück CE; Mullis PE; Pandey AV
Biochem Biophys Res Commun; 2010 Oct; 401(1):149-53. PubMed ID: 20849814
[TBL] [Abstract][Full Text] [Related]
4. Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization.
Marohnic CC; Huber Iii WJ; Patrick Connick J; Reed JR; McCammon K; Panda SP; Martásek P; Backes WL; Masters BS
Arch Biochem Biophys; 2011 Sep; 513(1):42-50. PubMed ID: 21741353
[TBL] [Abstract][Full Text] [Related]
5. Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase.
Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):64-70. PubMed ID: 27032764
[TBL] [Abstract][Full Text] [Related]
6. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase.
Pandey AV; Kempná P; Hofer G; Mullis PE; Flück CE
Mol Endocrinol; 2007 Oct; 21(10):2579-95. PubMed ID: 17595315
[TBL] [Abstract][Full Text] [Related]
7. Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.
Jin Y; Chen M; Penning TM; Miller WL
Biochem J; 2015 May; 468(1):25-31. PubMed ID: 25728647
[TBL] [Abstract][Full Text] [Related]
8. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.
Marohnic CC; Panda SP; McCammon K; Rueff J; Masters BS; Kranendonk M
Drug Metab Dispos; 2010 Feb; 38(2):332-40. PubMed ID: 19884324
[TBL] [Abstract][Full Text] [Related]
9. The reactions of heme- and verdoheme-heme oxygenase-1 complexes with FMN-depleted NADPH-cytochrome P450 reductase. Electrons required for verdoheme oxidation can be transferred through a pathway not involving FMN.
Higashimoto Y; Sato H; Sakamoto H; Takahashi K; Palmer G; Noguchi M
J Biol Chem; 2006 Oct; 281(42):31659-67. PubMed ID: 16928691
[TBL] [Abstract][Full Text] [Related]
10. Heme oxygenase-1 affects cytochrome P450 function through the formation of heteromeric complexes: Interactions between CYP1A2 and heme oxygenase-1.
Connick JP; Reed JR; Cawley GF; Backes WL
J Biol Chem; 2021; 296():100030. PubMed ID: 33148696
[TBL] [Abstract][Full Text] [Related]
11. Protein/protein interactions in the mammalian heme degradation pathway: heme oxygenase-2, cytochrome P450 reductase, and biliverdin reductase.
Spencer AL; Bagai I; Becker DF; Zuiderweg ER; Ragsdale SW
J Biol Chem; 2014 Oct; 289(43):29836-58. PubMed ID: 25196843
[TBL] [Abstract][Full Text] [Related]
12. The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer.
Yanatori I; Richardson DR; Toyokuni S; Kishi F
J Biol Chem; 2017 Aug; 292(32):13205-13229. PubMed ID: 28655775
[TBL] [Abstract][Full Text] [Related]
13. Identification of danthron as an isoform-specific inhibitor of HEME OXYGENASE-1/cytochrome P450 reductase interaction with anti-tumor activity.
Chou YT; Hsu FF; Hu DY; Chen YC; Hsu YH; Hsu JT; Chau LY
J Biomed Sci; 2018 Jan; 25(1):6. PubMed ID: 29361943
[TBL] [Abstract][Full Text] [Related]
14. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
Sandee D; Morrissey K; Agrawal V; Tam HK; Kramer MA; Tracy TS; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Nov; 20(11):677-86. PubMed ID: 20940534
[TBL] [Abstract][Full Text] [Related]
15. Biochemical analysis of mutations in P450 oxidoreductase.
Pandey AV
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1186-91. PubMed ID: 17073782
[TBL] [Abstract][Full Text] [Related]
16. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency.
Gomes LG; Huang N; Agrawal V; Mendonça BB; Bachega TA; Miller WL
J Clin Endocrinol Metab; 2008 Jul; 93(7):2913-6. PubMed ID: 18397975
[TBL] [Abstract][Full Text] [Related]
17. Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase.
Marohnic CC; Panda SP; Martásek P; Masters BS
J Biol Chem; 2006 Nov; 281(47):35975-82. PubMed ID: 16998238
[TBL] [Abstract][Full Text] [Related]
18. P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.
Miller WL
Sci Signal; 2012 Oct; 5(247):pt11. PubMed ID: 23092891
[TBL] [Abstract][Full Text] [Related]
19. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
Burkhard FZ; Parween S; Udhane SS; Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):38-50. PubMed ID: 27068427
[TBL] [Abstract][Full Text] [Related]
20. Expression and characterization of full-length human heme oxygenase-1: the presence of intact membrane-binding region leads to increased binding affinity for NADPH cytochrome P450 reductase.
Huber WJ; Backes WL
Biochemistry; 2007 Oct; 46(43):12212-9. PubMed ID: 17915953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
